Charles River Laboratories, Inc. (NYSE: CRL) today announced the opening of its new biomedical diagnostic testing facility in Wilmington, Massachusetts. The state-of-the-art, 60,000-square-foot R&D services facility expands the Company’s diagnostic capabilities for research model health monitoring, clinical chemistry, hematology, biomarker assay development and immunoassay services. The new facility offers high-functioning, controlled environments, building monitoring and mechanical systems redundancy, as well as energy reduction through occupancy sensor-driven air distribution and lighting.
“Our new facility provides Charles River with additional capacity for growth, as well as the capability to utilize innovative technology platforms to advance the high-quality R&D services we provide our biopharmaceutical and academic clients,” said James C. Foster, Chairman, President and Chief Executive Officer. “The opening of this building also demonstrates our commitment to investing in growth businesses and our employees, as well as doing business in the Commonwealth of Massachusetts.”
Charles River is one of the largest global preclinical contract research organizations, or CROs, with approximately 1,000 employees in Massachusetts and approximately 7,100 employees globally. In the 65 years since its founding in 1947, Charles River has expanded from a provider of high-quality research models to a full-service, early-stage CRO with a broad portfolio of essential products and services that support our clients’ drug discovery and development efforts.
About Charles River
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit